Deanna Dryhurst, PhD.
Chief Scientific Officer
Deanna Dryhurst received her BSc in Biology from the University of Victoria where she also received her PhD in the Department of Biochemistry and Microbiology. During her graduate studies, she worked on chromatin dynamics and epigenetics with a focus on prostate cancer. Deanna received an NSERC Industrial Research and Development Postdoctoral Fellowship to work on a platform for rabbit monoclonal antibody development at ImmunoPrecise Antibodies. She has been with ImmunoPrecise since 2010 and has been the Principal Investigator on an NRC IRAP grant and has collaborated with university faculty members on NSERC Engage grants.
Andra Li, PhD.
Director of Molecular Services
Andra Li has spent the past 6 years at IPA refining the rabbit monoclonal antibody technology platform and developing ImmunoProtect as part of their new service offerings. In addition to her role as Director, Dr. Li manages all operations of IPA’s molecular unit. Dr. Li holds a BSc and a PhD in Biochemistry from University of Victoria. During her graduate studies, she examined the role of histone variants in double stranded DNA repair. Dr. Li was awarded an NSERC Industrial Research and Development Postdoctoral Fellowship to generate single chain antibodies from rabbit monoclonal antibodies at ImmunoPrecise.
David Kroeger, PhD.
Senior Scientist, Director of Hybridoma Services
David Kroeger joined the IPA team in 2017 bringing with him a broad skillset in immunology, immuno-oncology, and antibody technology. He earned his PhD in immunology at the University of Saskatchewan in 2012 where he studied cellular interactions between B cells and T cells and their immunological outcomes. Dr. Kroeger then pursued postdoctoral training at the BC Cancer Agency. During his time, he studied the immune response to human cancer and made discoveries regarding the role of B cells in antitumor immunity. In addition to basic research, Dr. Kroeger made translational contributions including developing methods for cloning fully human antibodies from single tumor infiltrating B cells.